HLA Molecule Targeting for Tumor Diagnosis and Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current personalized tumor therapies face challenges in identifying effective diagnostic and therapeutic targets for cancer treatment due to the complexity of tumor biology and the need for precise molecular diagnostics, with existing methods having limited response rates and significant side effects.
Innovation Solution
A method involving the determination of specific nucleic acid molecule and protein or peptide expression in a subject, using sequences such as SEQ ID NOs 1 to 10, to produce a medicament that inhibits their expression or a diagnostic agent that detects them, specifically targeting HLA class Iw and other molecules for tumor treatment and diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If personalized tumor therapy is implemented based on molecular diagnostics, then treatment efficacy is improved, but device complexity and diagnostic complexity increase
Solution Approach 1:
The patent segments the complex tumor diagnostic process into specific modular components: detecting particular HLA molecules (HLA-H, HLA-J, HLA-L, HLA-V, HLA-Y) as distinct targets, analyzing specific genomic alterations, and evaluating particular protein expressions. This segmentation transforms the overwhelming complexity of comprehensive tumor profiling into manageable, targeted assessments of specific molecular markers, thereby improving treatment efficacy while reducing diagnostic complexity.
2Productivity
If targeted therapy against specific molecular mechanisms is used, then treatment response rate is improved, but manufacturing precision and target identification difficulty increase
Solution Approach 1:
The patent applies preliminary action by conducting comprehensive molecular diagnostics before treatment selection. Specifically, it performs preliminary identification of HLA molecule expressions, genomic alterations, and protein profiles to pre-determine the most appropriate targeted therapy. This advance molecular characterization ensures that patients receive precisely matched treatments based on their tumor's molecular features, thereby improving response rates while systematically addressing target identification challenges through standardized preliminary testing protocols.
3Ease of operation
If chemotherapy is used as backbone treatment, then ease of operation is maintained, but object-generated harmful factors increase due to side effects
Solution Approach 1:
The patent applies local quality by transitioning from uniform chemotherapy treatment to localized, molecule-specific targeted therapies. Instead of applying the same chemotherapy regimen to all patients, the treatment is customized based on the specific molecular characteristics of each patient's tumor (such as presence of HLA-H, HLA-J, HLA-L, HLA-V, or HLA-Y expressions). This localized approach delivers precise therapeutic intervention to the specific molecular targets driving each patient's cancer, thereby reducing unnecessary exposure to chemotherapy side effects while maintaining treatment accessibility through standardized diagnostic-guided protocols.
Data Source
AI summary
The present invention relates to a method for producing a medicament for the treatment or prevention of a tumor in a subject or a diagnostic agent for the detection of a tumor in a subject comprising (A) determining the expression of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from said subject, wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 5, (b) comprising or consisting of the nucleotide sequence of any one of SEQ ID NOs 6 to 10, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d), (f) consisting of a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides, and (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U, and wherein the at least one protein or peptide is selected from proteins or peptides being encoded by the nucleic acid molecule of any one of (a) to (g); and (B) producing a medicament capable of inhibiting the expression of the at least nucleic acid molecule and/or the at least one protein or peptide in the subject, if the at least one nucleic acid molecule and/or at least one protein or peptide is expressed in (A), and/or (B′) producing a diagnostic agent capable of detecting in vivo the sites of expression of the at least nucleic acid molecule and/or the at least one protein or peptide in the subject, if the at least one nucleic acid molecule and/or at least one protein or peptide is expressed in (A).